Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.

Postmenopausal Women ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer

Investigational New Drugs ◽

10.1007/s10637-016-0403-2 ◽

2016 ◽

Vol 35 (1) ◽

pp. 87-94 ◽

Cited By ~ 3

Author(s):

Murtuza Rampurwala ◽

Kari B. Wisinski ◽

Mark E. Burkard ◽

Sima Ehsani ◽

Ruth M. O’Regan ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Metastatic Breast ◽

Abstract P3-14-03: A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR+ MBC) and metastatic ovarian cancer (MOC)

10.1158/1538-7445.sabcs19-p3-14-03 ◽

2020 ◽

Author(s):

Christina I Herold ◽

Lorenzo Trippa ◽

Tianyu Li ◽

Khanh Do ◽

Aditya Bardia ◽

...

Keyword(s):

Breast Cancer ◽

Ovarian Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

Breast Cancer ◽

10.1007/s12282-019-01034-6 ◽

2019 ◽

Vol 27 (3) ◽

pp. 399-404 ◽

Cited By ~ 1

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

Qiuji Wu ◽

Feng Wen ◽

Nan Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis

Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralizing antibody, combined with exemestane (Ex) and everolimus (Ev) in hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (BC): primary phase 1b results.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.530 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 530-530 ◽

Cited By ~ 3

Author(s):

Javier Cortes ◽

Noelia Martinez Janez ◽

Marie-Paule Sablin ◽

Jose Alejandro Perez-Fidalgo ◽

Patrick Neven ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Hormone Receptor ◽

Locally Advanced ◽

Metastatic Breast ◽

Neutralizing Antibody ◽

Primary Phase ◽

Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-008-0232-x ◽

2008 ◽

Vol 112 (S1) ◽

pp. 53-66 ◽

Cited By ~ 12

Author(s):

Joseph Gligorov ◽

Jean-Pierre Lotz

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Treatment Strategies ◽

Metastatic Breast ◽

Optimal Treatment ◽

Molecular marker correlates of clinical outcome in a phase II study of gefitinib or placebo in combination with anastrozole in postmenopausal women with hormone receptor-positive metastatic breast cancer.

10.1158/0008-5472.sabcs-3131 ◽

2009 ◽

Cited By ~ 2

Author(s):

V Valero ◽

S Bacus ◽

A Mangalik ◽

I Rabinowitz ◽

F Arena ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Outcome ◽

Molecular Marker ◽

Postmenopausal Women ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Abstract P4-13-03: Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy

10.1158/1538-7445.sabcs15-p4-13-03 ◽

2016 ◽

Cited By ~ 1

Author(s):

S Verma ◽

AM DeMichele ◽

S Loi ◽

J Ro ◽

M Colleoni ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 3 ◽

Double Blind ◽

Abstract OT2-08-01: A phase 1b trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy with/without CDK 4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC)

10.1158/1538-7445.sabcs19-ot2-08-01 ◽

2020 ◽

Author(s):

Seth A. Wander ◽

Dejan Juric ◽

Laura M. Spring ◽

Neelima Vidula ◽

Maureen Beeler ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Metastatic Breast ◽

Akt Inhibitor ◽

Phase 1B ◽

Anti Tumor Activity

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3015-6 ◽

2014 ◽

Vol 146 (1) ◽

pp. 153-162 ◽

Cited By ~ 24

Author(s):

Mark J. Clemons ◽

Brandy Cochrane ◽

Gregory R. Pond ◽

Nadia Califaretti ◽

Stephen K. L. Chia ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Phase Ii ◽

Hormone Receptor ◽

Controlled Trial ◽

Metastatic Breast ◽

Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-012-1977-9 ◽

2012 ◽

Vol 71 (1) ◽

pp. 63-72 ◽

Cited By ~ 27

Author(s):

Francisco J. Esteva ◽

Stacy L. Moulder ◽

Ana M. Gonzalez-Angulo ◽

Joe Ensor ◽

James L. Murray ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Phase I Trial ◽

Metastatic Breast ◽